DUAC (benzoyl peroxide; clindamycin phosphate) by GSK is protein. First approved in 2002.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
DUAC is a topical gel combination of benzoyl peroxide and clindamycin phosphate used to treat acne vulgaris. Benzoyl peroxide acts as an oxidizing agent with bactericidal and keratolytic effects, while clindamycin provides antimicrobial activity against acne-causing bacteria. The dual mechanism targets both bacterial proliferation and inflammatory processes underlying acne pathogenesis.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition from growth to defensive brand management and potential right-sizing of commercial infrastructure.
protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
DUAC® Early Onset Efficacy Study in Japanese Subjects
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris
Worked on DUAC at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DUAC offers exposure to mature topical dermatology portfolio management and defensive commercial strategy as the product navigates LOE. Limited headcount expansion and career growth are expected; roles focus on profit protection, generic defense, and market share stabilization rather than innovation.